Clinical Trials Logo

Filter by:
NCT ID: NCT02184195 Completed - Clinical trials for Metastatic Adenocarcinoma of the Pancreas

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

POLO
Start date: December 16, 2014
Phase: Phase 3
Study type: Interventional

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

NCT ID: NCT02184117 Completed - Clinical trials for Coronary Artery Disease

CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)

CONTRAST
Start date: July 2014
Phase: N/A
Study type: Observational

The purpose of this study is to determine the diagnostic performances of iodine contrast medium and resting conditions to predict fractional flow reserve (FFR). Reference FFR will be measured using standard adenosine. We hypothesize that contrast FFR will offer superior diagnostic agreement compared to resting conditions.

NCT ID: NCT02183727 Terminated - Clinical trials for Acute Ruptures of the Anterior Cruciate Ligament

L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction

Start date: September 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare safety and efficacy outcomes of the L-C Ligament versus Hamstring Autograft for treatment of acute rupture of the ACL.

NCT ID: NCT02183454 Completed - Clinical trials for Coronary Artery Disease

MASCOT - Post Marketing Registry

MASCOT
Start date: June 2014
Phase: N/A
Study type: Observational [Patient Registry]

To collect post marketing surveillance data on patients receiving at least one Combo Bio-Engineered Sirolimus Eluting Stent when used according to the Instructions for Use. Data will be collected in order to assess the long term safety and performance of the Combo Stent in routine clinical practice.

NCT ID: NCT02182440 Completed - Acute Kidney Injury Clinical Trials

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

STOP-AKI
Start date: December 18, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.

NCT ID: NCT02181738 Completed - Hodgkin Disease Clinical Trials

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

CheckMate 205
Start date: August 12, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

NCT ID: NCT02181725 Completed - Chronic Pain Clinical Trials

2B Active: Outpatient Rehabilitation for Adolescents With Chronic Pain

Start date: July 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a multimodal rehabilitation program effectively reduces functional disability in adolescents with chronic musculoskeletal pain, compared to care as usual.

NCT ID: NCT02181686 Completed - Heart Failure Clinical Trials

Iperia/Sentus QP Study

Start date: July 2014
Phase: N/A
Study type: Observational

The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.

NCT ID: NCT02181413 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Start date: July 1, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

NCT ID: NCT02180815 Terminated - Clinical trials for Obstructive Sleep Apnea

REV 002 Observational Study of the ReVENT Sleep Apnea System: Minimally Invasive Treatment for Obstructive Sleep Apnea

Start date: September 2014
Phase: N/A
Study type: Observational

The purpose of this post-market observational study is to assess the effectiveness and patient perception of benefit of the ReVENT Sleep Apnea System in patients diagnosed with Obstructive Sleep Apnea due to primary tongue base closure. The ReVENT Sleep Apnea System is a minimally invasive surgical approach to treat Obstructive Sleep Apnea. The ReVENT Sleep Apnea System consists of an implanter kit and tongue implants. The implants are permanently implanted in the tongue during a minimally invasive outpatient surgical procedure to prevent tongue base closure during sleep.